方法：通过计算机和辅以手工检索1995/2012 年相关数据库及其他网络资源的相关资料，应用 MetaAnalyst 软件对其进行 Meta 分析。分析指标：泪道阻塞疾病的男女患病率，各种泪道疾病的患病率及Nd：YAG激光泪道成形手术治疗各种泪道阻塞疾病的有效率。

结果：根据纳入和排除标准筛选出38个研究对象，纳入患病人数累计4 638例，男性合并患病率23%； 女性合并患病率77%； 泪小点阻塞合并患病率6.0%，合并治疗有效率88.1%； 泪小管阻塞合并患病率17.9%，合并有效率85.6%； 泪总管阻塞合并患病率14.0%，合并有效率92.7%； 鼻泪管阻塞合并患病率43.6%，合并有效率93.3%； 慢性泪囊炎合并患病率18.4%，合并有效率76.6%。所有研究存在异质性。选用随机效应模型合并效应量。模型有统计学意义(P<0.001)。

结论：泪道阻塞疾病中女性患病率高于男性，泪小管阻塞在泪道阻塞中患病率最低，鼻泪管阻塞是泪道阻塞疾病的主要类型，Nd：YAG激光泪道成形手术治疗各种泪道阻塞疾病疗效略有差异。

METHODS: Relevant database in 1995-2012 and other network resources were retrieved by computer and manual, using MetaAnalyst software on the Meta analysis. Analysis of indicators: disease prevalence between men and women, the prevalence of various lacrimal duct diseases and the effective rate of Nd: YAG laser lacrimal duct forming surgery to treat a variety of lacrimal duct obstruction diseases.

RESULTS: According to the inclusion and exclusion criteria, 38 subjects were selected, the cumulative number of patients included 4 638 cases, the men combined prevalence was 23%; the women combined prevalence was 77%; lacrimal punctum occlusion combined prevalence was 6.0%, combined treatment efficiency was 88.1%; lacrimal canaliculus obstruction combined prevalence of 17.9%, combined efficiency was 85.6%; lacrimal common canaliculus obstruction combined prevalence was 14.0%, 92.7% of the combined effective rate; nasolacrimal duct obstruction combined prevalence of was 43.6%, 93.3% of the combined effective rate; chronic dacryocystitis combined prevalence was 18.4%, 76.6% of the combined efficiency. All study has heterogeneity. Selection of random effects model combined effect size. Model was statistically significant(P<0.001).

CONCLUSION: The prevalence of lacrimal duct obstruction diseases of women are higher than men, lacrimal canaliculus obstruction in the lacrimal duct obstruction is in the lowest prevalence, nasolacrimal duct obstruction is the main type of lacrimal duct obstruction disease, Nd: YAG laser lacrimal forming surgery has slightly efficacy different in various lacrimal duct obstruction diseases.